The venue for this event will be
The Stevenage Bioscience Catalyst, within the GSK complex, Stevenage, UK
The Stevenage Bioscience Catalyst campus is a unique bioscience community created to provide small biotech and life sciences companies and start-ups with access to the expertise, networks and scientific facilities traditionally associated with multinational pharmaceutical companies
This is a Euroscicon Small Conference, an outline of the day can be found at
This conference provides a platform for researchers, physicians and enterprisers to discuss and learn about all the important breakthrough developments in vaccine delivery and on new therapeutics and know what the new trend of the vaccine (drug) delivery technologies is in future and how these technologies can be developed, realized and commercialized. It also provides scientist the opportunity to present their cutting-edge researches in the area of vaccination, drug delivery, gene delivery, immunotherapy and nanotechnology. Throughout the course of the 1-day conference, you will have the opportunity to both expanding the network and hear leaders from the pharmaceutical, academic and clinical communities.
This event is part of the 2013 Euroscicon BioTherapeutics Week,
to find out more see www.biotherapeutics2013.com
This event has CPD accreditation
Meeting chair: Dr Lan Chen, Department of Chemical Engineering and Biotechnology University of Cambridge
Who Should Attend
Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research
Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chairs: Dr Lan Chen, Department of Chemical Engineering and Biotechnology University of Cambridge
10:00 – 10:30 Non-Replicating Viral Vaccines and Novel Antigen Delivery System
Professor Polly Roy, London School of Hygiene & Tropical Medicine, UK
10:30 – 11:00 Development of Novel Antibody-Inducing Vaccines against Human Malaria
Dr Simon Draper, The Jenner Institute, University of Oxford
The human malaria parasite Plasmodium falciparum continues to exert a huge burden on global public health, whilst the development of a highly efficacious vaccine has proved extremely challenging. The disease-causing blood-stage of the parasite’s life-cycle is known to be susceptible to antibodies. However, the field has faced significant hurdles in translating this knowledge into efficacious clinical subunit vaccine products. This talk will focus on the development of new approaches to vaccine antigen identification and delivery in the context of human malaria, and will summarise experience to date of these new strategies in Phase I/IIa clinical trials.
11:00 – 11:30 Speakers’ photo then mid-morning break and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:30 – 12:00 Novel generation of bacteriophage-derived platform technologies for vaccine delivery
Dr Amin Hajitou, Imperial College Faculty of Medicine Division of Brain Sciences, Hammersmith Hospital, United Kingdom
12:00 – 12:30 Multifunctional Nanoparticle - new platform for vaccine delivery
Dr Lan Chen, Department of Chemical Engineering and Biotechnology University of Cambridge
Great advances have been made in the past decades on the development of vaccine delivery but the dilemma between immunogenicity, safety and tolerability has remained a major challenge and not been well overcome. Therefore, it needs to develop smarter delivery solutions to overcome this weakness. A smart drug delivery system is the system that can act accurately only in targeted tissue and make diagnosis and provide therapy during the same time. To achieve these functions, a custom made nano-platform will firstly be built. Then, various therapy cargos will be loaded onto the platform according to requirement, where the cargos are not only chemical substances but any active components, like fluorescent tags, antibodies, peptides and DNA. Eventually, healthcare delivery at low cost, low side-effect, high efficacy and long-lasting manners will be achieved.
12:30 – 13:30 Lunch and trade show
13:30 – 14:00 Assessment of a newly developed medical device for intradermal vaccination: results of a phase 1 trial in 102 healthy volunteers
Dr Vanessa Vankerckhoven, VAXINFECTIO (Vaccine & Infectious Disease Institute), University of Antwerp, Belgium
To date, the vast majority of vaccines are administered into the muscle (intramuscular) using needle and syringe. The past years renewed interest has been shown in intradermal vaccination due to its advantages. However, devices to accurately deliver vaccines in the dermal layer of the skin are scarce. The project approach with a distinct university-SME collaboration ultimately led to the development of a prototype device, entitled VAX-ID®. Results of a Phase 1 trial in which intramuscular and intradermal vaccination was compared in 102 healthy volunteers will be discussed.
14:00 – 14:30 Nanoparticle Tracking Analysis: Visualizing, sizing and counting viruses in liquid suspension.
Ben Owen, Product Specialist, Nanosight, UK
A laser-based nanoparticle tracking analysis system is now available which allows nanoscale particles such as viruses and virus aggregates to be directly and individually visualised in liquids in real-time, from which high-resolution particle size distribution profiles can be obtained. The technique is fast, robust, accurate and low cost representing an attractive alternative or complement to existing methods of nanoparticle analysis such as Dynamic Light Scattering (DLS), Photon Correlation Spectroscopy (PCS) or Electron Microscopy (EM).
14:30 – 15:00 Afternoon Tea/Coffee and trade show
15:00– 15:30 Ensuring Sterilising Filtration of Advanced Vaccine Formulations
Dr Annelies Onraedt, Pall Europe, UK
Advanced vaccine formulations, typically associated with new delivery systems such as adjuvanted vaccines or virus-like-particles can present major challenges to sterilising filtration. In order to comply with cGMP, these challenges and the associated risks have to be understood and mitigated early in process development so that marketing applications to, and product approvals by regulatory authorities are not unnecessarily delayed. In this presentation an overview of the challenges and risks are presented whilst some corrective approaches are proposed.
15:30 - 16:00 Approaches to T cell vaccines for HIV
Dr Steven Patterson, Imperial College at Chelsea and Westminster Hospital, UK
An effective HIV vaccine is thought to require T cell responses. T cell immune responses induced by acute infection or a vaccine are usually limited to recognition of a small number of immunodominant or subdominant epitopes. This presents a major hurdle in the development of a T cell vaccine for HIV since a high mutation rate enables the virus to quickly escape immune recognition. Vaccine strategies designed to induce responses to multiple T cell epitopes and overcome the problem of immune escape will be described.
16: 00 - 17:00 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day
17:00 Chairman’s summing up
About the Speakers
Polly Roy began her education in Calcutta, India but won a fellowship to New York University for her PhD under the supervision of the renowned molecular biologist, Sol Spiegleman. A 3-year postdoctoral position in virology at the Waksman Institute, Rutgers University, followed after which she joined the University of Alabama at Birmingham to establish her own virology research group where she became a full Professor in 1986. In 1987 she received a senior International Fogarty fellowship to study at the University of Oxford where she gradually established a UK-based research group. In 1997, she became Professor at the University of Oxford and in 2001 took the chair of Virology at the London School of Hygiene and Tropical Medicine. Her studies have contributed in many areas of virology, notably virus structure, assembly, RNA replication and vaccine development. Roy was the first to demonstrate the assembly of virus-like particles (VLPs), a technology which has been applied since to many other viruses including for successful vaccine development for Human Papillomavirus, Influenza and SARS. Recently Roy pioneered the synthesis of infectious virus solely from synthetic genes, a major achievement which opens a new window of opportunity for the development of new therapies in the longer term. She has supervised over 140 post-doctoral and post-graduate researchers, published over 300 research papers and has served on various international scientific organizations, committees and boards. She has organized several highly successful international conferences, particularly on the subject of virus assembly and in 2006 was elected a Fellow of the Academy of Medical Sciences. This year Roy has received a Gold Medal for her contribution to science and technology from the Indian Prime Minister during the Annual Indian Science Congress (2012), along with three Nobel laureates. She is also one of the three BBSRC Scientific Innovators of the year.
Ben Owen’s background is in biomedical science, with an expertise in diagnostic markets. Ben has specialised in pharmacology and biochemistry, and holds an honours degree from Cardiff University. After several years working in drug development for GlaxoSmithKline and Johnson and Johnson, Ben began working on the development of gold and silver nanoparticles for the diagnostic markets as a senior research scientist at British Biocell International. Ben has been working in the field of nanotechnology for the last 5 years; he is currently a product specialist and business development manager for Nanosight, responsible for sales and scientific support in southern UK, Denmark, Norway and Sweden.
Simon Draper’s group is based at the Jenner Institute, University of Oxford. His research interests include studies of vaccine-induced malaria immunity as well as the optimisation of antibody induction by subunit vaccines against blood-stage malaria infection. In recent years, his group has developed novel vaccines targeting blood-stage antigens from the human malaria parasite Plasmodium falciparum, and these have been translated into Phase I/IIa clinical trials. His group are also focusing on the identification of new antigen combinations that may prove to be more successful in inducing protective efficacy against malaria by subunit vaccination in humans.
Steven Patterson is based in the Immunology Department at Imperial College’s Chelsea and Westminster Campus where the main research focus of department is HIV. His main research interests are in HIV pathogenesis, vaccines and human dendritic cell biology. Since the mid 1980s his group have investigated the role of dendritic cells in HIV pathogenesis and but in the last six years they have been funded by the Bill and Melinda Gates Foundation to develop a T cell vaccine for HIV that will overcome the problem of virus escape from immune recognition.
Vanessa Vankerckhoven is currently appointed as Research & Innovation Manager of the Vaccine and Infectious Disease Institute at the University of Antwerp. She obtained a master degree in Biomedical Sciences and a PhD in Medical Sciences at the University of Antwerp, Belgium. Her main research interests are in vaccines as well as medical device development such as injection devices and point of care diagnostics. She has been working on the development of an injection device suited for intradermal vaccination. As an R&I manager she is also responsible for assessing technology transfer and valorisation opportunities including patent filing and spin-off creation.
Annelies Onraedt, PhD, is Global Market Manager for Vaccines at Pall Life Sciences, a Total Solutions provider for the Biopharmaceutical industry. She obtained a PhD in Bioscience Engineering from Ghent University, Belgium, for her study in the field of Industrial Microbiology and Biocatalysis. She then joined Pall as a Biopurification Specialist and has several years of experience in optimizing downstream processing technologies for the vaccine industry, including chromatography, tangential and direct flow filtration. In her current position as vaccine market manager, she is in frequent contact with the vaccine industry worldwide. She is involved in the development of integrated manufacturing solutions, new technology platforms and strategic collaboration programs. She is a frequent speaker at conferences and seminars on latest market and technology trends.
Keywords: Malaria; Vaccine; Antibody; Immunology,Vaccine delivery; Immunotherapy; Nanoparticles, Drug-delivery; Gene-Delivery, HIV, vaccine, T cells , Medical device, human volunteers, vaccines, university-industry collaboration, intradermal vaccination, Nanoparticle: charactersation; technique; size; count
Registration Web Site: www.regonline.co.uk/vaccines2013
Phone: 07507 799380
For accommodation and travel please contact firstname.lastname@example.org
For enquiries regarding payment email: email@example.com
You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
Payment must be received prior to the meeting
You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process). After registration you will be emailed details of where to send your cheque.
Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly
Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration. After registration you will be emailed details of where transfer your money.
EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5 4LQ, UK. Trading address BioPark, Broadwater Road , Hertfordshire, AL7 3AX , UK